The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | The impact of acoramidis on clinical outcomes in ATTR-CM
In this video, Daniel Judge, MD, Medical University of South Carolina, Charleston, SC, outlines the results from a prespecified analysis of the ATTRibute-CM trial (NCT03860935), which explored the safety and efficacy of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The Phase III trial had previously shown the benefit of this drug, and this research confirmed these results by finding a marked improvement in patients who were treated compared to the placebo group. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy fees: BridgeBio
